Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03227146Phase 2Active Not Recruiting

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Role: collaborator

NCT03229564Phase 2Active Not Recruiting

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children

Role: collaborator

NCT03394612Phase 2Active Not Recruiting

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Role: collaborator

All 3 trials loaded